{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:10:51Z","timestamp":1772741451456,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s44446-025-00058-8","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:12:55Z","timestamp":1768299175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-2468","authenticated-orcid":false,"given":"Thamir M.","family":"Alshammari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"58_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030339","author":"R Abdelsalam Elshenawy","year":"2024","unstructured":"Abdelsalam Elshenawy R, Umaru N, Aslanpour Z (2024) Shorter and longer antibiotic durations for respiratory infections: to fight antimicrobial resistance-a retrospective cross-sectional study in a secondary care setting in the UK. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph17030339","journal-title":"Pharmaceuticals (Basel)"},{"key":"58_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/jrpp.jrpp_55_22","volume":"11","author":"M Adhimoolam","year":"2022","unstructured":"Adhimoolam M, Akili K (2022) Azithromycin-Induced Generalized Nonbullous Fixed-Drug Eruption. J Res Pharm Pract 11:162\u2013164. https:\/\/doi.org\/10.4103\/jrpp.jrpp_55_22","journal-title":"J Res Pharm Pract"},{"key":"58_CR3","unstructured":"Al Aboud DM, Nessel\u00a0TA, Hafsi W (2025) Cutaneous adverse drug reaction.\u00a0StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Trevor Nessel declares no relevant financial relationships with ineligible companies.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30422592. Accessed May 2025"},{"key":"58_CR4","doi-asserted-by":"publisher","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","volume":"15","author":"KA Alenzi","year":"2024","unstructured":"Alenzi KA, Alsuhaibani D, Batarfi B et al (2024) Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol 15:1364110. https:\/\/doi.org\/10.3389\/fphar.2024.1364110","journal-title":"Front Pharmacol"},{"key":"58_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.642822","volume":"12","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alqarni M et al (2021) Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Front Pharmacol 12:642822. https:\/\/doi.org\/10.3389\/fphar.2021.642822","journal-title":"Front Pharmacol"},{"key":"58_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jsps.2018.04.012","volume":"26","author":"TM AlShammari","year":"2018","unstructured":"AlShammari TM, Almoslem MJ (2018) Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multi-centre cross sectional study. Saudi Pharm J 26:925\u2013931. https:\/\/doi.org\/10.1016\/j.jsps.2018.04.012","journal-title":"Saudi Pharm J"},{"key":"58_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/DHPS.S497112","volume":"17","author":"H Alshareef","year":"2025","unstructured":"Alshareef H, Alenzi KA, Albalawi BR et al (2025) Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study. Drug Healthc Patient Saf 17:51\u201362. https:\/\/doi.org\/10.2147\/DHPS.S497112","journal-title":"Drug Healthc Patient Saf"},{"key":"58_CR8","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1111\/ajd.12563","volume":"58","author":"I An","year":"2017","unstructured":"An I, Demir V, Akdeniz S (2017) Fixed drug eruption probably induced by azithromycin. Australas J Dermatol 58:e253\u2013e254. https:\/\/doi.org\/10.1111\/ajd.12563","journal-title":"Australas J Dermatol"},{"key":"58_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090925","author":"HJ Anderson","year":"2021","unstructured":"Anderson HJ, Lee JB (2021) A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina57090925","journal-title":"Medicina (Kaunas)"},{"key":"58_CR10","first-page":"121","volume":"102","author":"C Armstrong","year":"2020","unstructured":"Armstrong C (2020) Community-acquired pneumonia: updated recommendations from the ATS and IDSA. Am Fam Physician 102:121\u2013124","journal-title":"Am Fam Physician"},{"issue":"3","key":"58_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5195\/ijms.2020.646","volume":"8","author":"J Aushal","year":"2020","unstructured":"Aushal J, Rakesh A (2020) Fixed drug eruption: a rare case of polysensitivity between two unrelated fixed dose combination preparations - a case report. Int J Med Students 8(3):291\u2013294. https:\/\/doi.org\/10.5195\/ijms.2020.646","journal-title":"Int J Med Students"},{"key":"58_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40290-018-0244-8","volume":"32","author":"ND Ayd\u0131nkarahalilo\u011flu","year":"2018","unstructured":"Ayd\u0131nkarahalilo\u011flu ND, Ayka\u00e7 E, Atalan \u00d6 et al (2018) Spontaneous reporting of adverse drug reactions by consumers in comparison with healthcare professionals in Turkey from 2014 to 2016. Pharmaceutical Medicine 32:353\u2013364. https:\/\/doi.org\/10.1007\/s40290-018-0244-8","journal-title":"Pharmaceutical Medicine"},{"issue":"No. RR-2","key":"58_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","volume":"73","author":"L Bachmann","year":"2024","unstructured":"Bachmann L, Barbee L, Chan PEA (2024) CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep 73(No. RR-2):1\u20138. https:\/\/doi.org\/10.15585\/mmwr.rr7302a1","journal-title":"MMWR Recomm Rep"},{"key":"58_CR14","first-page":"26","volume":"13","author":"H Baldwin","year":"2020","unstructured":"Baldwin H (2020) Oral antibiotic treatment options for acne vulgaris. J Clin Aesthet Dermatol 13:26\u201332","journal-title":"J Clin Aesthet Dermatol"},{"key":"58_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.37201\/req\/143.2023","volume":"37","author":"J Barberan","year":"2024","unstructured":"Barberan J, de la Cuerda A, Tejeda Gonzalez MI et al (2024) Safety of fluoroquinolones. Rev Esp Quimioter 37:127\u2013133. https:\/\/doi.org\/10.37201\/req\/143.2023","journal-title":"Rev Esp Quimioter"},{"key":"58_CR16","doi-asserted-by":"publisher","unstructured":"Barisic, V., T. Kovacevic, M. Travar, et al., 2025. A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics (Basel). 14, https:\/\/doi.org\/10.3390\/antibiotics14060535","DOI":"10.3390\/antibiotics14060535"},{"key":"58_CR17","doi-asserted-by":"publisher","unstructured":"Bednarcuk, N., A. Golic Jelic, S. Stoisavljevic Satara, et al., 2023. Antibiotic Utilization during COVID-19: Are We Over-Prescribing? Antibiotics (Basel). 12, https:\/\/doi.org\/10.3390\/antibiotics12020308","DOI":"10.3390\/antibiotics12020308"},{"key":"58_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1046\/j.0303-4569.2001.00473.x","volume":"34","author":"ME Beutel","year":"2002","unstructured":"Beutel ME, Schumacher J, Weidner W et al (2002) Sexual activity, sexual and partnership satisfaction in ageing men\u2013results from a German representative community study. Andrologia 34:22\u201328. https:\/\/doi.org\/10.1046\/j.0303-4569.2001.00473.x","journal-title":"Andrologia"},{"key":"58_CR19","doi-asserted-by":"publisher","unstructured":"Bradley, J. S., M. A. Jackson, D. Committee on Infectious, et al., 2011. The use of systemic and topical fluoroquinolones. Pediatrics. 128, e1034\u20131045. https:\/\/doi.org\/10.1542\/peds.2011-1496","DOI":"10.1542\/peds.2011-1496"},{"key":"58_CR20","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1111\/jdv.20280","volume":"39","author":"A Brehon","year":"2025","unstructured":"Brehon A, Lourenco J, Badaoui A et al (2025) Doxycycline-induced fixed drug eruption: the new epidemic? J Eur Acad Dermatol Venereol 39:e303\u2013e305. https:\/\/doi.org\/10.1111\/jdv.20280","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"58_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3947\/ic.2024.0030","volume":"56","author":"J Chae","year":"2024","unstructured":"Chae J, Choi YM, Kim YC et al (2024) Quinolone use during the first trimester of pregnancy and the risk of atopic dermatitis, asthma, and allergies of offspring during 2011 to 2020. Infect Chemother 56:461\u2013472. https:\/\/doi.org\/10.3947\/ic.2024.0030","journal-title":"Infect Chemother"},{"key":"58_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jiph.2021.02.001","volume":"14","author":"M Chedid","year":"2021","unstructured":"Chedid M, Waked R, Haddad E et al (2021) Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health 14:570\u2013576. https:\/\/doi.org\/10.1016\/j.jiph.2021.02.001","journal-title":"J Infect Public Health"},{"key":"58_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3345\/kjp.2013.56.5.196","volume":"56","author":"SH Choi","year":"2013","unstructured":"Choi SH, Kim EY, Kim YJ (2013) Systemic use of fluoroquinolone in children. Korean J Pediatr 56:196\u2013201. https:\/\/doi.org\/10.3345\/kjp.2013.56.5.196","journal-title":"Korean J Pediatr"},{"key":"58_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.876695","volume":"3","author":"L Di Bartolomeo","year":"2022","unstructured":"Di Bartolomeo L, Irrera N, Campo GM et al (2022) Drug-induced photosensitivity: clinical types of phototoxicity and photoallergy and pathogenetic mechanisms. Front Allergy 3:876695. https:\/\/doi.org\/10.3389\/falgy.2022.876695","journal-title":"Front Allergy"},{"key":"58_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/TCRM.S314923","volume":"17","author":"K Dorobisz","year":"2021","unstructured":"Dorobisz K, Dorobisz T, Janczak D et al (2021) Doxycycline in the coronavirus disease 2019 therapy. Ther Clin Risk Manag 17:1023\u20131026. https:\/\/doi.org\/10.2147\/TCRM.S314923","journal-title":"Ther Clin Risk Manag"},{"key":"58_CR26","unstructured":"FDA, 2024. Food and Drug Administration.Potential Signals of Serious Risks\/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS), January - March 2024. United States Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/january-march-2024-potential-signals-serious-risksnew-safety-information-identified-fda-adverse . Accessed on April 2025."},{"key":"58_CR27","unstructured":"FDA, TYGACIL\u00ae (2025) Food and drug administration. TYGACIL\u00ae (tigecycline) for injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021821s056lbl.pdf . Accessed Nov 2025"},{"key":"58_CR28","unstructured":"FDA (2025) Food and Drug Administration. Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. The United States Food and Drug Administration. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed May 2025"},{"key":"58_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024a) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"58_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024b) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf 47:585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"key":"58_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/13543784.2022.2054325","volume":"31","author":"J Garrido-Mesa","year":"2022","unstructured":"Garrido-Mesa J, Adams K, Galvez J et al (2022) Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications. Expert Opin Investig Drugs 31:475\u2013482. https:\/\/doi.org\/10.1080\/13543784.2022.2054325","journal-title":"Expert Opin Investig Drugs"},{"key":"58_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030104","author":"LA Hamilton","year":"2019","unstructured":"Hamilton LA, Guarascio AJ (2019) Tetracycline allergy. Pharmacy (Basel). https:\/\/doi.org\/10.3390\/pharmacy7030104","journal-title":"Pharmacy (Basel)"},{"key":"58_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.medcle.2020.06.026","volume":"155","author":"V Herrera-Lasso Regas","year":"2020","unstructured":"Herrera-Lasso Regas V, Dordal Culla MT, Lleonart Bellfill R (2020) Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. Medicina Cl\u00ednica (English Edition) 155:448\u2013453. https:\/\/doi.org\/10.1016\/j.medcle.2020.06.026","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"key":"58_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ddg.14314","volume":"19","author":"GA Hofmann","year":"2021","unstructured":"Hofmann GA, Weber B (2021) Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. JDDG J Dtsch Dermatol Ges 19:19\u201329. https:\/\/doi.org\/10.1111\/ddg.14314","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"58_CR35","doi-asserted-by":"publisher","unstructured":"Hrovat, K., K. Seme and J. Ambrozic Avgustin, 2024. Increasing Fluroquinolone Susceptibility and Genetic Diversity of ESBL-Producing E. coli from the Lower Respiratory Tract during the COVID-19 Pandemic. Antibiotics (Basel). 13, https:\/\/doi.org\/10.3390\/antibiotics13090797","DOI":"10.3390\/antibiotics13090797"},{"key":"58_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-224858","author":"M Iliyas","year":"2018","unstructured":"Iliyas M, Reddy MRS, Devi U (2018) Ciprofloxacin-induced generalised non-bullous fixed drug eruption. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2018-224858","journal-title":"BMJ Case Rep"},{"key":"58_CR37","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_874_20","volume":"66","author":"A Jadhav","year":"2021","unstructured":"Jadhav A, Patil S, Manchanda I et al (2021) Cutaneous adverse drug reactions in a tertiary teaching hospital: a prospective, observational study. Indian J Dermatol 66:573. https:\/\/doi.org\/10.4103\/ijd.ijd_874_20","journal-title":"Indian J Dermatol"},{"key":"58_CR38","doi-asserted-by":"publisher","first-page":"744","DOI":"10.7860\/JCDR\/2013\/4757.2901","volume":"7","author":"SP Jain","year":"2013","unstructured":"Jain SP, Jain PA (2013) Bullous fixed drug eruption to ciprofloxacin: a case report. J Clin Diagn Res 7:744\u2013745. https:\/\/doi.org\/10.7860\/JCDR\/2013\/4757.2901","journal-title":"J Clin Diagn Res"},{"key":"58_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107391","volume":"26","author":"M Jiang","year":"2023","unstructured":"Jiang M, Yang J, Yang L et al (2023) An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese. iScience 26:107391. https:\/\/doi.org\/10.1016\/j.isci.2023.107391","journal-title":"iScience"},{"key":"58_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M (2020) Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res 51:741\u2013742. https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004","journal-title":"Arch Med Res"},{"key":"58_CR41","unstructured":"Kommu , S., Carter. C and W. P., 2024. Adverse Drug Reactions. [Updated 2024 Jan 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599521\/. Accessed\u00a0May 2025"},{"key":"58_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081063","author":"GG Kournoutou","year":"2022","unstructured":"Kournoutou GG, Dinos G (2022) Azithromycin through the lens of the COVID-19 treatment. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11081063","journal-title":"Antibiotics"},{"key":"58_CR43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa1215","volume":"72","author":"PM Lantos","year":"2021","unstructured":"Lantos PM, Rumbaugh J, Bockenstedt LK et al (2021) Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis 72:e1\u2013e48. https:\/\/doi.org\/10.1093\/cid\/ciaa1215","journal-title":"Clin Infect Dis"},{"key":"58_CR44","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jama.2024.11437","volume":"332","author":"EY Lee","year":"2024","unstructured":"Lee EY, Gomes T, Drucker AM et al (2024) Oral antibiotics and risk of serious cutaneous adverse drug reactions. JAMA 332:730\u2013737. https:\/\/doi.org\/10.1001\/jama.2024.11437","journal-title":"JAMA"},{"key":"58_CR45","doi-asserted-by":"publisher","first-page":"1117391","DOI":"10.3389\/fphar.2023.1117391","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Gou J, Zhu J et al (2023a) Severe cutaneous adverse reactions to drugs: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Front Pharmacol 14:1117391. https:\/\/doi.org\/10.3389\/fphar.2023.1117391","journal-title":"Front Pharmacol"},{"key":"58_CR46","doi-asserted-by":"publisher","first-page":"1181633","DOI":"10.3389\/fcimb.2023.1181633","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Liu L, Zhang H et al (2023b) Severe problem of macrolides resistance to common pathogens in China. Front Cell Infect Microbiol 13:1181633. https:\/\/doi.org\/10.3389\/fcimb.2023.1181633","journal-title":"Front Cell Infect Microbiol"},{"key":"58_CR47","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC et al (2023) Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 388:1296\u20131306. https:\/\/doi.org\/10.1056\/NEJMoa2211934","journal-title":"N Engl J Med"},{"key":"58_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14030207","author":"R Mahmud","year":"2025","unstructured":"Mahmud R, Krullaars Z, van Osch J et al (2025) Computational and population-based HLA permissiveness to HIV drug resistance-associated mutations. Pathogens. https:\/\/doi.org\/10.3390\/pathogens14030207","journal-title":"Pathogens"},{"key":"58_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2015.11.017","volume":"28","author":"AV Marzano","year":"2016","unstructured":"Marzano AV, Borghi A, Cugno M (2016) Adverse drug reactions and organ damage: the skin. Eur J Intern Med 28:17\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2015.11.017","journal-title":"Eur J Intern Med"},{"key":"58_CR50","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/ddg.14870","volume":"20","author":"J McClatchy","year":"2022","unstructured":"McClatchy J, Yap T, Nirenberg A et al (2022) Fixed drug eruptions - the common and novel culprits since 2000. JDDG: Journal der deutschen Dermatologischen Gesellschaft 20:1289\u20131302. https:\/\/doi.org\/10.1111\/ddg.14870","journal-title":"JDDG: Journal der deutschen Dermatologischen Gesellschaft"},{"key":"58_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00705-020-04860-8","volume":"166","author":"JA Mosquera-Sulbaran","year":"2021","unstructured":"Mosquera-Sulbaran JA, Hernandez-Fonseca H (2021) Tetracycline and viruses: a possible treatment for COVID-19? Arch Virol 166:1\u20137. https:\/\/doi.org\/10.1007\/s00705-020-04860-8","journal-title":"Arch Virol"},{"key":"58_CR52","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.45055","volume":"7","author":"AO Nakitanda","year":"2024","unstructured":"Nakitanda AO, Odsbu I, Cesta CE et al (2024) First trimester tetracycline exposure and risk of major congenital malformations. JAMA Netw Open 7:e2445055. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.45055","journal-title":"JAMA Netw Open"},{"key":"58_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","volume":"56","author":"R Neha","year":"2021","unstructured":"Neha R, Subeesh V, Beulah E et al (2021) Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength. Hosp Pharm 56:152\u2013158. https:\/\/doi.org\/10.1177\/0018578719882323","journal-title":"Hosp Pharm"},{"key":"58_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2013","unstructured":"Noren GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"key":"58_CR55","unstructured":"Patel, P. H. and M. F. Hashmi, 2025. Macrolides. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies"},{"key":"58_CR56","doi-asserted-by":"publisher","unstructured":"Poluzzi. E, Raschi. E., C. Piccinni, and , et al., 2012. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS),\u201d in Data mining applications in engineering and medicine (IntechOpen). https:\/\/doi.org\/10.5772\/50095","DOI":"10.5772\/50095"},{"key":"58_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2:349\u2013351. https:\/\/doi.org\/10.2165\/00128071-200102060-00001","journal-title":"Am J Clin Dermatol"},{"key":"58_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/cdr.Cdr_109_20","volume":"5","author":"L Rajendran","year":"2021","unstructured":"Rajendran L, Thyvalappil A, Sridharan R et al (2021) A study of cutaneous adverse drug reactions in a tertiary care center in South India. Clinical Dermatology Review 5:173\u2013177. https:\/\/doi.org\/10.4103\/cdr.Cdr_109_20","journal-title":"Clinical Dermatology Review"},{"key":"58_CR59","unstructured":"Regunath, H. and Y. Oba, 2024. Community-Acquired Pneumonia. [Updated 2024 Jan 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430749\/. Accessed Oct 2025"},{"issue":"1006","key":"58_CR60","doi-asserted-by":"publisher","first-page":"e1001","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE et al (2024) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 90(1006):e1001-1006e1030. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.017","journal-title":"J Am Acad Dermatol"},{"key":"58_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40264-018-0703-x","volume":"42","author":"JR Rogers","year":"2019","unstructured":"Rogers JR, Sarpatwari A, Desai RJ et al (2019) Effect of lawyer-submitted reports on signals of disproportional reporting in the Food and Drug Administration\u2019s adverse event reporting system. Drug Saf 42:85\u201393. https:\/\/doi.org\/10.1007\/s40264-018-0703-x","journal-title":"Drug Saf"},{"key":"58_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes L, van Hunsel F, Taxis K et al (2016) The impact of experiencing adverse drug reactions on the patient\u2019s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf 39:769\u2013776. https:\/\/doi.org\/10.1007\/s40264-016-0422-0","journal-title":"Drug Saf"},{"key":"58_CR63","unstructured":"Sabih A, Leslie SW (2024) Complicated Urinary Tract Infections. [Updated 2024 Dec 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK436013\/. Accessed\u00a0May 2025"},{"issue":"236\u2013237","key":"58_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.09.024","volume":"13","author":"P Shrestha","year":"2025","unstructured":"Shrestha P, Stone CA Jr, Phillips EJ (2025) Fixed drug eruption and generalized bullous fixed drug eruption: Insights from an analysis of the FDA Adverse Event Reporting System. J Allergy Clin Immunol Pract 13(236\u2013237):e231. https:\/\/doi.org\/10.1016\/j.jaip.2024.09.024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"58_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101144","author":"EM Sokolewicz","year":"2021","unstructured":"Sokolewicz EM, Rogowska M, Lewandowski M et al (2021) Antibiotic-related adverse drug reactions in patients treated on the dermatology ward of Medical University of Gdansk. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics10101144","journal-title":"Antibiotics"},{"key":"58_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf062","volume":"12","author":"SW Sunagawa","year":"2025","unstructured":"Sunagawa SW, Codling G, Lyden E et al (2025) Utilization of doxycycline postexposure prophylaxis at a Midwestern United States HIV\/PrEP clinic. Open Forum Infect Dis 12:ofaf062. https:\/\/doi.org\/10.1093\/ofid\/ofaf062","journal-title":"Open Forum Infect Dis"},{"key":"58_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-84800-165-7_18","volume-title":"Clinical and Basic Immunodermatology","author":"CK Svensson","year":"2008","unstructured":"Svensson CK (2008) Drug Eruptions. In: Gaspari AA, Tyring SK (eds) Clinical and Basic Immunodermatology. London, Springer, London, pp 263\u2013276"},{"key":"58_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238255","author":"D Takenaka","year":"2020","unstructured":"Takenaka D, Nishizawa T (2020) Morbilliform drug eruptions caused by trimethoprim-sulfamethoxazole. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2020-238255","journal-title":"BMJ Case Rep"},{"key":"58_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdcr.2024.10.012","volume":"56","author":"S Talasila","year":"2025","unstructured":"Talasila S, Waseh S, Liu JY et al (2025) Semaglutide-induced fixed drug eruption. JAAD Case Rep 56:5\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2024.10.012","journal-title":"JAAD Case Rep"},{"key":"58_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101072","volume":"18","author":"X Tang","year":"2025","unstructured":"Tang X, Lin L, Yu F et al (2025) Allergic-related skin diseases: global disease burden from 1990 to 2021 and future trends. World Allergy Organ J 18:101072. https:\/\/doi.org\/10.1016\/j.waojou.2025.101072","journal-title":"World Allergy Organ J"},{"key":"58_CR71","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/ph18070957","volume":"18","author":"HA Thaibah","year":"2025","unstructured":"Thaibah HA, Banji OJF, Banji D et al (2025) Suicidality risks associated with finasteride, a 5-alpha reductase inhibitor: an evaluation of real-world data from the FDA adverse event reports. Pharmaceuticals 18:957","journal-title":"Pharmaceuticals"},{"key":"58_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020214","author":"HA Thaibah","year":"2025","unstructured":"Thaibah HA, Banji OJF, Banji D et al (2025b) Diabetic ketoacidosis and the use of new hypoglycemic groups: real-world evidence utilizing the Food and Drug Administration adverse event reporting system. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18020214","journal-title":"Pharmaceuticals (Basel)"},{"key":"58_CR73","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s0895-4356(98)00041-9","volume":"51","author":"PD van der Linden","year":"1998","unstructured":"van der Linden PD, van der Lei J, Vlug AE et al (1998) Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 51:703\u2013708. https:\/\/doi.org\/10.1016\/s0895-4356(98)00041-9","journal-title":"J Clin Epidemiol"},{"key":"58_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG et al (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"58_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5826\/dpc.0101a09","volume":"1","author":"W Weyers","year":"2011","unstructured":"Weyers W, Metze D (2011) Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept 1:33\u201347. https:\/\/doi.org\/10.5826\/dpc.0101a09","journal-title":"Dermatol Pract Concept"},{"key":"58_CR76","doi-asserted-by":"publisher","first-page":"1183491","DOI":"10.3389\/fphar.2023.1183491","volume":"14","author":"CH Wung","year":"2023","unstructured":"Wung CH, Wang CW, Lai KC et al (2023) Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs. Front Pharmacol 14:1183491. https:\/\/doi.org\/10.3389\/fphar.2023.1183491","journal-title":"Front Pharmacol"},{"key":"58_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.813213","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Geng X, Liu X et al (2022) Antibiotic use in China\u2019s public healthcare institutions during the COVID-19 pandemic: an analysis of nationwide procurement data, 2018\u20132020. Front Pharmacol 13:813213. https:\/\/doi.org\/10.3389\/fphar.2022.813213","journal-title":"Front Pharmacol"},{"key":"58_CR78","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/ds.DS-D-24-00275","volume":"43","author":"J-W Yeh","year":"2025","unstructured":"Yeh J-W, Liu W-T (2025) Fixed drug eruption \u2013 a retrospective review of 146 patients in a tertiary hospital in Southern Taiwan. Dermatol Sin 43:124\u2013128. https:\/\/doi.org\/10.4103\/ds.DS-D-24-00275","journal-title":"Dermatol Sin"},{"issue":"945\u2013973","key":"58_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ et al (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74(945\u2013973):e933. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.037","journal-title":"J Am Acad Dermatol"},{"key":"58_CR80","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","volume":"61","author":"J Zhang","year":"2021","unstructured":"Zhang J, Lei Z, Xu C et al (2021) Current perspectives on severe drug eruption. Clin Rev Allergy Immunol 61:282\u2013298. https:\/\/doi.org\/10.1007\/s12016-021-08859-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"58_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ye X, Guo X et al (2021) Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol 12:766125. https:\/\/doi.org\/10.3389\/fphar.2021.766125","journal-title":"Front Pharmacol"},{"key":"58_CR82","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12016-021-08919-5","volume":"62","author":"LJ Zhu","year":"2022","unstructured":"Zhu LJ, Liu AY, Wong PH et al (2022) Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides. Clin Rev Allergy Immunol 62:505\u2013518. https:\/\/doi.org\/10.1007\/s12016-021-08919-5","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-025-00058-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:31:35Z","timestamp":1772739095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-025-00058-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s44446-025-00058-8","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The author declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}